Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The prospects of using the methods of gene engineering for the development of viral vaccines are considered. The technological and biological barriers hampering the introduction of these biotechnological methods into the practice of vaccinal prophylaxis are analyzed. The work points out that in the near future successes may be achieved in synthetizing the internal proteins M and NP of influenza viruses and similar proteins of paramyxoviruses and rhabdoviruses, as well as in using yeast for the production of vaccine against hepatitis B.
 ...
PMID:[Various problems of biotechnology]. 638 76

The seven major childhood infectious diseases-measles, mumps, rubella, polio, diphtheria, pertussis, and tetanus-can cause permanent disability and, in some cases, death. They all can be prevented by immunization, but prior to the National Childhood Immunization Initiative of 1977 more than a third of all children under age 15 were not properly protected. And even though vaccines are now available to reduce the risk of influenza, hepatitis B, and pneumococcal pneumonia, many high risk patients are not protected. Outbreaks of measles and pertussis, and occasionally of diphtheria and polio, during the mid-1970s indicate that immunization must be emphasized continually. With the combination of safe, effective vaccines, public and private programs, and a reliable disease surveillance and outbreak containment system, infectious diseases can be controlled. The Department of Health and Human Services has proposed a major initiative designed to eliminate the indigenous occurrence of measles.
 ...
PMID:Preventive health services: Immunization. 641 18

The secretion of gamma-interferon (IFN-gamma), Interleukin-2 (IL-2), and B cell growth factor (BCGF) by human T cell clones specific for hepatitis B surface antigen (HBsAg) was examined. Antigenic stimulation by HBsAg but not by influenza A virus resulted in IFN-gamma and BCGF synthesis by the T cell clones. No detectable amounts of IL-2 were obtained in the supernatants of any of the HBsAg-specific T cell clones when cultured in the presence or absence of antigen. IFN-gamma and BCGF were produced, even when cell proliferation was inhibited, suggesting that the secretion of these T cell factors occurred regardless of cell proliferation. The significance of the various factors in the immune response against hepatitis B virus infection is discussed.
 ...
PMID:Antigen-induced production of lymphokines by human T cell clones specific for hepatitis B surface antigen. 643 96

Rabies is one of the oldest diseases know to man, but its successful control has remained elusive. Although effective vaccines of tissue culture origin against rabies do exist, such preparations are expensive. Live vaccinia virus (VV) recombinants expressing influenza or hepatitis B antigens have recently been used to immunize against these diseases. We have now used this approach to produce a novel rabies vaccine. We first altered the rabies glycoprotein cDNA by site-directed mutagenesis and removed the poly(dG) tail. We then aligned the modified cDNA with an early VV promoter sequence inserted within a cloned copy of the vaccinia thymidine kinase gene and transfected this plasmid into VV-infected cells. Recombination between the virus and the plasmid resulted in a recombinant virus harbouring the rabies glycoprotein cDNA. Inoculation of rabbits with the live recombinant virus induced high titres of rabies virus-neutralizing antibodies, and scarification with the recombinant VV protected mice against challenge with street rabies virus.
 ...
PMID:Expression of rabies virus glycoprotein from a recombinant vaccinia virus. 654 99

Genetic engineering (recombinant DNA technology)--the revolution in molecular biology--has enabled us to isolate any genes from any source in a pure form, and to move them from one cell to another. It has become possible to program bacterial or yeast cells with foreign genes and force the new host to produce commercially valuable proteins (e.g. hormones, enzymes, diagnostic reagents). It is now also possible to produce viral and bacterial antigens in various types of cells. We hope that this will soon enable us to manufacture vaccines cheaply. The production of a foot-and-mouth-disease virus vaccine--the first promising example of a genetically engineered effective vaccine--has recently been reported. Expression of hepatitis B surface antigen, influenza virus haemagglutinin and polio-virus proteins from the cloned genes have also been reported, and many more viral genes have been cloned although not yet expressed in bacteria. Despite the extremely rapid development, there are a number of problems, both technical and immunological, which have to be extensively studied and eventually solved, before we can hope to obtain effective and safe genetically engineered viral vaccines for clinical use.
 ...
PMID:Genetically engineered viral vaccines--prospects for the future. 676 95

Passive immunization is available against rabies, varicella, tetanus and hepatitis A and B. Active immunization is, in general, more efficacious with live attenuated viruses than with many of the bacterial vaccines. Toxoids, too, are very effective immunizing agents. Immunization usually starts at two months of age with DTP and oral poliovirus vaccine. For patients at high risk for secondary complications, influenza and pneumococcal immunizations are advisable. Hepatitis B vaccine is now available for persons at high risk because of their occupations.
 ...
PMID:Immunization update. 682 79

High-affinity 125I-labelled monoclonal antibodies to hepatitis B virus surface antigen (HBsAg) bind to human hepatocellular carcinoma cell line, PLC/PRF/5, which synthesizes and secretes HBsAg. These monoclonal antibodies of the IgG1, IgG2a, and IgM isotypes are directed against different antigenic determinants on HBsAg and, in the presence of complement, both anti-HBs IgG2a and IgM, but not anti-HBs IgG1, lyse PLC/PRF/5 cells in culture. Although there is a low level of anti-HBs binding (especially with anti-HBs IgM) to human hepatoma cell lines which do not synthesize HBsAg (SK-Hep 1 and Mahlavu cells), this interaction does not lead to complement-mediated cell lysis and is thought to be nonspecific. Minimal binding of 125I-labeled anti-influenza HA antigen IgM binding to PLC/PRF/5 cells was also detected, but this likewise did not lead to complement-mediated cell lysis. These results indicate that a human hepatocellular carcinoma cell line, persistently infected with hepatitis B virus, can be recognized and lysed by monoclonal antibodies directed against specific determinants of HBsAg. Monoclonal antibodies to this viral envelope protein may prove to be useful immunodiagnostic and immunotherapeutic agents when such viral epitopes are expressed on the surface of infected cells.
 ...
PMID:Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen. 695 17

This review discusses the indications for the routine immunizations covered by the Swiss "Immunization Schedule 1981" (diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, BCG), as well as the indications for special immunizations (hepatitis B, influenza, pneumococci, rabies, tickencephalitis) and for the immunisations for travellers (cholera, yellow fever, meningococci, typhoid fever). Vaccination against measles, mumps and rubella should be given to girls and boys at the age of 18 (to 24) months as a combined injection. In view of the low prevalence of tuberculosis BCG vaccination is justifiable only at school leaving age, if at all. The indications for influenza and pneumococcal vaccines are still limited, the value of a general vaccination of all over 65 year old individuals is not proven for either vaccine. A nationwide vaccination campaign against hepatitis B was started early this year with a newly licensed vaccine for all population groups at risk. Only HDC-vaccines should be used for immunisation against rabies. The newly licensed, highly protective oral attenuated live typhoid vaccine will probably replace the parenteral typhoid vaccine.
 ...
PMID:[Vaccination: 1982 status]. 713 94

In eight patients with biopsy-confirmed chronic active hepatitis (CAH), hepatitis B e antigen (HBeAg) levels and DNA polymerase (DNA-P) activity were assayed three times a week for six weeks and once a week for another six weeks. HBeAg levels were rather constant, whereas DNA-P activity fluctuated. No correlation was observed between the quantities of HBeAg and DNA-P activity. An unexpected fluctuation in DNA-P activity was noted in all patients after an influenza vaccination.
 ...
PMID:Quantitative relationship between HBeAg and DNA polymerase activity in sera from patients with chronic active hepatitis during a three-month period. 722 20

Immunization of infants and children is the most effective strategy for decreasing the incidence of some infectious diseases. Most invasive disease due to Haemophilus influenzae type b occurs before age 5 years, and routine vaccination of infants for hepatitis B is currently recommended because selective immunization of high-risk persons has not been feasible. Decades of use of poliovirus vaccine has effectively eliminated cases of wild-virus infection, although some vaccine-related cases still occur. The newly approved varicella vaccine appears to be a cost-effective way to decrease infection rates in children. Improved immunization rates for influenza and pneumococcal and meningococcal diseases could help decrease excess mortality in elderly persons and those with chronic illness.
 ...
PMID:Vaccination update. Hib, hepatitis, polio, varicella, influenza, pneumococcal and meningococcal disease. 747 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>